-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JlEjnp8C0AgaQkLG1uzzDR0VYjSsw5jCRGjCV9Xh2JeXAPSj0naK82ID4EcTYhvO 6jnz/0BlsMkiTzQqfPUfFg== 0001209191-08-044869.txt : 20080801 0001209191-08-044869.hdr.sgml : 20080801 20080801183058 ACCESSION NUMBER: 0001209191-08-044869 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20081031 FILED AS OF DATE: 20080801 DATE AS OF CHANGE: 20080801 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kaye Randall CENTRAL INDEX KEY: 0001350416 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15803 FILM NUMBER: 08986299 BUSINESS ADDRESS: BUSINESS PHONE: 858-622-5200 MAIL ADDRESS: STREET 1: 11388 SORRENTO VALLEY ROAD STREET 2: STE. 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVANIR PHARMACEUTICALS CENTRAL INDEX KEY: 0000858803 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330314804 STATE OF INCORPORATION: CA FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 101 ENTERPRISE STREET 2: SUITE 300 CITY: ALISO VIEJO STATE: CA ZIP: 92656 BUSINESS PHONE: 949-389-6700 MAIL ADDRESS: STREET 1: 101 ENTERPRISE STREET 2: SUITE 300 CITY: ALISO VIEJO STATE: CA ZIP: 92656 FORMER COMPANY: FORMER CONFORMED NAME: LIDAK PHARMACEUTICALS DATE OF NAME CHANGE: 19920703 4 1 doc4.xml FORM 4 SUBMISSION X0303 4 2008-10-31 0 0000858803 AVANIR PHARMACEUTICALS AVNR 0001350416 Kaye Randall 101 ENTERPRISE, SUITE 300 ALISO VIEJO CA 92656 0 1 0 0 Sr. VP, Chief Medical Officer Stock Option (right to buy) 0.88 2008-10-31 5 A 0 E 29900 0.00 A 2018-07-25 Class A Common Stock 29900 29900 D Stock Option (right to buy) 0.88 2008-12-31 5 A 0 E 89700 0.00 A 2018-07-25 Class A Common Stock 89700 89700 D Stock Option (right to buy) 0.88 2009-07-31 5 A 0 E 179400 0.00 A 2018-07-25 Class A Common Stock 179400 179400 D The transaction date for the acquisition of this performance option will be the date when the reporting person achieves certain performance goals. See footnotes 3, 5 and 7 below. Reflects the maximum number of shares available for purchase upon exercise of this option if all the performance goals are met. See footnotes 3, 5 and 7 below. On July 25, 2008, the reporting person was granted an option to purchase up to 29,900 shares of common stock of the Issuer. The option vests and becomes exercisable following the achievement of certain performance goals relating to the clinical development of Zenvia, as follows: 29,900 shares will vest if the performance goals are met on or before October 31, 2008; 27,950 shares will vest if the performance goals are met between November 1 and November 30, 2008; 26,000 shares will vest if the performance goals are met between December 1 and December 31, 2008; 18,200 shares will vest if the performance goals are met between January 1 and February 28, 2009; and none of the shares will vest if the performance goals are met on or after March 1, 2009. Upon achievement of the performance goals, the option will vest with respect to 6.25% of the underlying shares and will continue to vest with respect to 6.25% of the underlying shares on a quarterly basis over 15 quarters. Although this option has a ten-year term from the grant date of July 25, 2008, the option will expire and be forfeited if the performance goals are not met by February 28, 2009. On July 25, 2008, the reporting person was granted an option to purchase up to 89,700 shares of common stock of the Issuer. The option vests and becomes exercisable following the achievement of certain performance goals relating to the clinical development of Zenvia, as follows: 89,700 shares will vest if the performance goals are met on or before December 31, 2008; 83,850 shares will vest if the performance goals are met between January 1 and February 15, 2009; 78,000 shares will vest if the performance goals are met between February 16 and March 31, 2009; 54,600 shares will vest if the performance goals are met between April 1 and June 30, 2009; and none of the shares will vest if the performance goals are met on or after July 1, 2009. Upon achievement of the performance goals, the option will vest with respect to 6.25% of the underlying shares and will continue to vest with respect to 6.25% of the underlying shares on a quarterly basis over 15 quarters. Although this option has a ten-year term from the grant date of July 25, 2008, the option will expire and be forfeited if the performance goals are not met by June 30, 2009. On July 25, 2008, the reporting person was granted an option to purchase up to 179,400 shares of common stock of the Issuer. The option vests and becomes exercisable following the achievement of certain performance goals relating to the clinical development of Zenvia, as follows: 179,400 shares will vest if the performance goals are met on or before July 31, 2009; 167,700 shares will vest if the performance goals are met between August 1 and September 15, 2009; 156,000 shares will vest if the performance goals are met between September 16 and October 31, 2009; 109,200 shares will vest if the performance goals are met between November 1, 2009 and January 31, 2010; and none of the shares will vest if the performance goals are met on or after February 1, 2010. Upon achievement of the performance goals, the option will vest with respect to 6.25% of the underlying shares and will continue to vest with respect to 6.25% of the underlying shares on a quarterly basis over 15 quarters. Although this option has a ten-year term from the grant date of July 25, 2008, the option will expire and be forfeited if the performance goals are not met by January 31, 2010. /s/ Christine G. Ocampo, by power of attorney 2008-08-01 -----END PRIVACY-ENHANCED MESSAGE-----